

JAZZ PHARMACEUTICALS PLC
CHARTER OF THE SCIENCE AND MEDICINE COMMITTEE OF THE BOARD OF
DIRECTORS

STATEMENT OF PURPOSE

Jazz Pharmaceuticals plc (the “*Company*”) together with the other subsidiaries of the Company (direct and indirect), including the Company form part of the Jazz Pharmaceuticals group of companies (the “*Group*”).

The purpose of the Science and Medicine Committee (the “*Committee*”) of the Board of Directors (the “*Board*”) of the Company as set forth in this charter (the “*Charter*”) is to review research, development, and technology (“*R&D*”) initiatives. The Committee will also discuss significant emerging trends and issues in science and technology and consider the potential impact thereof on the Company. It is the responsibility of the Company’s management, and not the Committee, to develop, design and/or implement the Company’s research and development strategy or program. Moreover, the purpose of the Committee is to provide advice and act in a consultative capacity to the Company, it does not have any decision-making capabilities with respect to any R&D initiatives.

The operation of the Committee shall be subject to the Constitution of the Company and the Irish Companies Act 2014 (the “*Act*”), each as in effect at the time of any action by the Committee.

COMPOSITION

The Committee shall consist of at least three members of the Board. Each member of the Committee shall be an “independent director” as such term is defined under the Company’s independence standards, the listing standards of The Nasdaq Stock Market LLC, as amended from time to time, and the rules and regulations of the Securities and Exchange Commission.

The members of the Committee, including the Chairperson, shall be appointed annually by the Board upon recommendation of the Nominating and Corporate Governance Committee of the Board, and may be replaced or removed by the Board at any time with or without cause. Resignation or removal of the Director from the Board, for whatever reason, shall automatically constitute resignation or removal, as applicable, from this Committee. Vacancies occurring, for whatever reason, may be filled by the Board.

MEETINGS AND MINUTES

The Committee shall hold such regular or special meetings as its members deem necessary or appropriate. Minutes of each meeting of the Committee shall be prepared and distributed to each director of the Company and the Secretary of the Company promptly after each meeting. The Chairperson of the Committee shall report to the Board from time to time and whenever so requested by the Board. The Committee may meet in person, video conference or by conference

Confidential.

telephone or other communications equipment by means of which all persons participating in the meeting can hear each other. A majority of the members of the Committee shall constitute a quorum for purposes of holding a meeting and the Committee may act by a vote of a majority of members present at such meeting. In lieu of a meeting, the Committee may act by unanimous written consent in accordance with the Company's Constitution.

OPERATING PRINCIPLES AND PROCESSES

In fulfilling its function and responsibilities, the Committee should give due consideration to the following operating principles and processes:

- Communication – Regular and meaningful contact throughout the year with the Board, committee chairpersons, members of senior management, independent professional advisors to the Board and its various committees and boards and /or committees of relevant Group members, as applicable, is viewed as important for strengthening the Committee's knowledge of relevant current and prospective R&D strategy of the Group.
- Resources – The Committee shall be authorized to access such internal and external resources as the Committee deems necessary or appropriate to fulfill its defined responsibilities, including engagement of independent counsel, consultants and other professional advisors. The Committee shall have the authority to approve fees, costs and other terms of engagement of such outside resources.
- General Authority – The Committee shall have the authority to perform such other functions and exercise such other powers as may be necessary or appropriate in the efficient discharge of its advisory responsibilities expressly provided by this Charter. The Committee shall have the authority to delegate any of its responsibilities, along with the authority to take action in relation to such responsibilities, to one or more subcommittees as the Committee may deem appropriate in its sole discretion.

RESPONSIBILITIES

The Committee has the following duties and responsibilities:

- Review and advise management and the Board regarding the strategy, direction, value and progress of the Company's R&D programs, pipeline and technology platforms.
- Review and advise management and the Board (including the Transaction Committee of the Board, as appropriate) on pertinent scientific, technological and medical elements of the Company's corporate development opportunities and transactions.
- Review and advise management and the Board on the Company's R&D resource allocation strategy, including internal and external investments, investment

allocation across R&D stages across franchises/therapeutic areas and technology platforms.

- Identify and discuss new and emerging trends in pharmaceutical and biotechnological science, technology, and regulation.
- Periodically review and assess the adequacy of this Charter and submit any changes to the Board for approval.
- Review the Committee's performance on an annual basis and present the results of its self-assessment and performance evaluation to the Board or its designee.
- Perform any other activities consistent with the Company's Constitution, related governing documents and applicable law as the Board or the Committee deems appropriate.

GENERAL

In carrying out its responsibilities, the Committee shall be entitled to rely upon advice and information that it receives in its discussions and communications with management.

The Committee may perform such other functions as may be requested by the Board from time to time.

* * * * *

Adopted 28 April 2022.